TypeOnline Course
Student Enrolled3
Price$390 / Rs. 19500
Buy NowBook Now

Admission Process

Admission Process

Sign in or create account at www.nckpharma.com with all details and make the course fees payment to start the course

Sign Up Now

Introduction

Feature

Eligibility

Admission Process

Course Code: KPE-C-078

Course Title: Advance Diploma in  Pharma Business Development & Licensing (ADBDL)

Course Mode: Online elearning

Course Objectives:

Pharmaceutical Business Development & Licensing courses are conceptualized with vision to create effective Business Development Manager for Pharmaceutical and biopharmaceutical Industry. This course gives practical knowledge of the functionalities of BD Manager with practical exposure.

Career in Business Development (BD) in Pharmaceutical, Biopharmaceutical Industry 

A career in Business Development (BD) is both a challenging and highly rewarding career in pharmaceutical and biopharmaceutical industry.  It opens up lot of opportunities as it covers a variety of disciplines. BD professionals involved in pipeline and portfolio management. In all established pharmaceutical company there are dedicated Business Development department (BD) and they take care of filing of the patent, trademark, issuing and management of the licensing etc. They work in close proximity with strategic management, regulatory team in company.

BD professionals should have

1. In depth understanding of R&D – Discovery to Commercialization Process
2. Hands on knowledge on drug discovery, development and regulatory aspects of the market.
3. Market research skills to Conduct extensive market vigilance studies to monitor market dynamic.
4. Decision making skills to understand market analysis, technical and commercial feasibility
5. Advance licensing skills like identifying potential partners / distributors for new products, In-licensing, distribution, dormant licenses

BD professionals should have a strong Business Acumen & closely partner with Business needs and requirement.

The current pharmacy syllabus of most of the pharmacy courses do not provide adequate practical exposure on Business Development (BD) functionalities, licensing business models of innovator & generic companies and the BD functioning in the entire pharma R&D to commercialization cycle.

This online course is aimed to fulfill these gaps and is uniquely designed for the pharmacy students, professionals and scientists working in the pharma industry so that they can learn the essentials and can better advance in their careers.

Our Registerants are in Takeda, Pfizer, GSK, Lipoxen (UK), Patheon, Mylan, Biocon, Micro Lab, GE Lifesciences, Orchid, Sanofi, AstraZeneca, Hospira, Ranbaxy, Julphar, Jhonson and Jhonson, Ethicon, Dr. Reddy’s Laboratory, MSD, Medo Pharma, Nestle, Ind-Swift, Panacea, Bal Pharma, Aristo, Reliance Lifesciences, Quality Pharma Pvt Ltd, Cipla, Ipca, Sherya Lifesciences, Promed, Torrent Pharmaceuticals, Zydus Candila, Himalaya Herbal Healthcare, Bangalore Pharmaceutical and Research laboratories, Teru Technomed, Indocoar Pharma, Fortis Hospitals, VRPL Healthcare, Medreich, Hospira, Indospectrum, Wintac Limited, Faveo Pharmaceuticals, Enzem, Leo Pharma, Accenture, Shaigan Pharmaceutical, Ceutica & Chemie, Medxplor Healthcare, Systopic Laboratories and many more companies across the pharma industry.

  • 24×7 Online Access – Access anytime from anywhere across globe.
  • Prinatable booklet provided to all course participants. 
  • Access the e-lectures, case studies, self assessment modules and practical sessions through personalized webpage. 
  • Flexible online final examination (Computer Based Test by secure mode)
  • Real life Case Study module will be provided along with the course ,material. 

B.Pharma/D.Pharma/ B.Sc/ Any graduates or those who are in 3rd / final year of those courses, who want to make career in pharmaceutical marketing can pursue the course.

FAQ RELATED TO THE COURSE

Frequently asked questions

Read FAQs

ADMISSION PROCESS

Course Flow – 

Section 1US BD Fundamental - Drug Discovery to Development
Lecture 1Drug Discovery - Development Process
Lecture 2Investigational New Drug Application
Lecture 3New Drug Application (NDA)
Lecture 4Basic concept and understanding of the Generic Drug
Lecture 5Abbreviated New Drug Application (ANDA)
Lecture 6Detailed learning on clinical trials and related terminologies
Lecture 7Practical Training on Handling of orange book
Lecture 8USFDA Expedited Programs (Detailed Understanding)
Lecture 9505(j) ANDA, 505(b)(2) NDA, 505(b)(1) NDA
Lecture 10Authorized Generics: Key Understanding
Lecture 11Exploratory IND
Lecture 12Patents Vs. exclusivity
Lecture 13Advance Learning on 505B2 Pathway
Lecture 14Chemistry, Manufacturing & Controls 
Lecture 15Orphan Drug Designation 
Lecture 16Advance Strategic Learning on 505B2 Pathway
Lecture 17Patent & Exclusivity - Strategic Understanding | Patent Restoration| Orphan Drug Exclusivity (ODE) | NCE & NCI Exclusivity | GAIN Exclusivity | Pediatric Exclusivity | 180 days exclusivity
Section 2EU BD Fundamental - Drug Discovery, Development & Strategic Planning
Lecture 18Introduction to EU Regulation 
Lecture 19Orientation to European Countries and National Regulatory Bodies
Lecture 20EU Drug Discovery Development to Commercialization (Step By Step)
Lecture 21Overview of EU Regulation 
Lecture 22EMA and EMA Authorisation Process
Lecture 23EU MA Application Types and Strategic Planning
Lecture 24EU MA Procedure - Centralised, Decentralised, Mutual Recognition, National Procedure 
Lecture 25EU MA Strategic Planning: Full, Full-mixed, hybrid applications. Generic, Similar biologic application pathway, Well-established use application, Fixed combination application, Informed consent application
Lecture 26Validity of the EU MA  - Renewal steps, Cessation of the marketing authorisation, Significance of "Placed in Union Market", Suspension or withdrawal & EU MA for licensed products
Lecture 27Data Exclusivity and Market Protection - Supplementary Patent Protection, Exclusivity, 6/10 Rule, 8+2+1 Formulae
Lecture 28EU Orphan Medicinal Products Regulation
Lecture 29Conditional marketing authorisation | Marketing authorisation under exceptional circumstances
Lecture 30Paediatric use marketing authorisation (PUMA) & Paediatric Investigation Plan (PIP)
Lecture 31EU variation - Types, Requirement & Planning - IA, IAIN, IB, II ; US FDA Variation AR, CBE-0, CBE-30, PAS - Strategic Discussion | Similarities & Differentiation
Lecture 32EU Prime Designation 
Lecture 33Accelerated assessment by EMEA
Lecture 34EU Adaptive Pathway
Lecture 35European public assessment report (EPAR) - Importance, Component, Management, Updation 
Lecture 36SPOR  - Concept of Master Data Management  
Lecture 37The 'sunset clause' for marketing authorisation of pharmaceuticals
Section 3IPR Management in Pharma and Biopharma Industry
Lecture 38Patent office - Introductions
Lecture 39Patent - Understanding Patentability, Novelty And Non-Obviousness, Conditions For Obtaining A Patent, Who can apply
Lecture 40Patent Application Process - USPTO
Lecture 41Trademark Search and Registration in US
Lecture 42Steps Know How & Key Points - Patent Application
Lecture 43IPR - Patent Grant and Handling Process in India (Optional)
Lecture 44Patent Search in Indian Patent Office (Optional)
Lecture 45Trademark - Practical on TM Search & Registration Process in India (Practical)
Lecture 46 Trademark Search assignment
Lecture 47Fundamental Understanding of Patent, Trademark Licensing and related terminology
Section 4Portfolio & Strategic Management
Lecture 48Portfolio Management in R&D Lifecycle 
Lecture 49Advance study on Para IV Filing
Lecture 50Para IV Notice
Lecture 51Evergreening - Patent Life Extension Strategies
Lecture 52Pay For Delay Strategy
Lecture 53REMS Strategic Planning
Lecture 54Compulsory Licensing
Lecture 55Technology Licensing
Lecture 56In-Licensing Vs. Outlicensing
Lecture 57Loss of Exclusivity (LOE) Strategies for Innovator Brands with case study
Lecture 58Paediatric Exclusivity and Paediatric Study Plan Development
Lecture 59Drug Re-purposing
Lecture 60Detailed Understanding on 505(b)(2) VS. Suitability Petition : Case Based Learning
Lecture 61NCE Vs. 505b2 application - Case Based Learning 
Lecture 62FTF - 180 Days Exclusivity
Lecture 63Classic case study of the 505b2 filing
Lecture 64Strategic Planning in Combating 30 months stay strategies of innovator compan
Section 5Licensing in Pharma Industry (Advance Practical Understanding)
Lecture 65License Agreement - Introduction
Lecture 66Licensing and Technology Transfer (TT)
Lecture 67In-Licensing Vs. Outlicensing
Lecture 68Why would a pharma company look for in-licensing deals?
Lecture 69Licensing agreement Types - Advance Learning
Lecture 70Duration and Terms of License
Lecture 71Key understanding: Are improvements licensed?
Lecture 72Financial terms of license - Upfront, Milestone and Royalty
Lecture 73Calculation of Total Deal Value
Lecture 74Milestone Payment
Lecture 75Royalty Management - How are royalties structured in a license?
Lecture 76What accounts, inspection and audit provisions are in a license?
Lecture 77How is patenting dealt with in a license?
Lecture 78What warranties are in a license?
Lecture 79What competition law issues are there in licensing?
Lecture 80Quick Glance: What are the Disadvantages of the in-licensing deals?
Lecture 81Step by Step Implementation of the licensing deal
Lecture 82STRATEGIC ALLIANCES: CO-DEVELOPMENT AND CO-MARKETING AGREEMENTS
Lecture 83Due Diligence Activities in Pharmaceutical Licensing
Section 6Financials of Business Development
Lecture 84Basic Understanding financial accounting and reporting
Lecture 85Financial performance measurement and working capital and cash flow
Lecture 86Long term decision making
Lecture 87Financial modelling
Lecture 88Valuation methods and management of risks
Section 7Project Management Skill Training for Business Development professionals
Lecture 89Definition Review
Lecture 90Difference between Project and Program
Lecture 91Phasing of Projects for better effectiveness / outcome of the Project 
Lecture 92Project Management Constraint
Lecture 93Key to Project Success
Lecture 94PROJECT MANAGEMENT TOOLS AND TECHNIQUES - PERT, CPM, CRITICAL PATH, PROJECT DIAGRAM AND ITS COMPONENTS
Lecture 95Qualities of a Good Project Leader
Lecture 96Qualities of a Good Team Representative
Lecture 97Project Tracking in Drug Discovery Projects
Lecture 98What to Track in project?
Lecture 99Project Benchmarking through a Consortium
Lecture 100Cycle Times (Stage or phase lengths)
Lecture 101Importance of The proof of concept (POC) milestone in pharma Drug Development Projects
Lecture 102Challenges to Milestone Dates
Lecture 103Project Terminations
Lecture 104Project Re-initiations
Lecture 105Asset Tracking
Lecture 106Levels of Project and Portfolio Management
Section 8Business Development Strategic Planning Process
Lecture 107Business Development Job Functionality | Strategic Planning Process | Knowledge Area of Business Development | Lead targeting | Licensing term sheets
Lecture 108Portfolio Management Process | Portfolio Characteristics | Portfolio Analysis | Balancing the Portfolio | BD and Strategic Planning Department 
Lecture 109Identifying the corporate Need of business development | Objective – Strategy - Tactics | Portfolio constraints | SWOT | Numerical SWOT
Lecture 110Profiling and Searching | Objectives | Search Database | Creating Opportunity Anatomy for deal analysis | Mind Mapping | Searching Tools and Techniques - Web Search | Conference | Confidentaility - CDA | MTA
Lecture 111Numerical SWOT Practical training
Lecture 112Modelling and Deal Valuation - Top Down Model | Epidemiology data method | Complex Model | Forecasting | Heuristic or ‘prophesy’ method | Different value perspectives | Deal Structuring Structuring the deal |
Lecture 113Market Size Determination - Market Share | Relative Market Share | Total Vs. Actual Vs. Penetrated Market
Lecture 114Forecasting : Tools and Techniques
Lecture 115Market Sizing & Forecasting Case Study
Lecture 116Royalty Management - Royalty structuring | Royalty Calculation Method| Tiered Royalties | Terms | Royalty Reductions | Royalty Stacking - Concept and Calculation | Minimum Annual Royalties | Reach through royalties
Lecture 117Average Royalty Rates
Lecture 118Factor affecting the Royalty Rate in Pharmaceutical and Biopharmaceutical Deal
Lecture 119Distribution Licensing | Geography | Indication Splitting | Execlusive and Non-Exclusive Licensing | Sub Licenses
Lecture 120Acquisition in Pharmaceutical and Biopharmaceutical Brands and Business
Lecture 121Joint Venture - Key Insight
Lecture 122Special Purpose Vehicle (SPV)
Lecture 123Indication Splitting | Concept | Implementation feasibility analysis 
Lecture 124Types of Deals from Discovery to Commerialication
Lecture 125Review: Fundamental Problem Area in Pharma Business Development
Lecture 126Licensing Term Sheet | Content Structuring | Sample Term Sheet
Lecture 127Licensing Payment Scheduling: Different Types
Lecture 128Valuation Methods: DCF | rNPV | Sunk Cost Method | Comparables | Sum of Parts | Deterministic Vs. Probabilistic rNPV |  Peak Sales - Max-Min Approach
Lecture 129EBITDA method of valuation | Enterprise Value and Enterprise Multiple Calculation
Section 9Final Examination
, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,